Early data from clinical trials did show marginal clinical response in myeloid malignancies, such as AML or myelodysplastic syndrome (MDS), when using mAbs targeting CTLA4 or PD-1/PD-L1 as single agents (37, 38, 71, 72). This evidence concerns the gene PDCD1 and myeloid neoplasm.